Abstract Several factors contribute to the pervasive Black-White disparity in breast cancer mortality in the U.S., such as tumor biology, access to care, and treatments received including adjuvant hormonal therapy (AHT), which significantly improves survival for hormone receptor-positive breast cancers (HR?). We analyzed South Carolina Central Cancer Registry-Medicaid linked data to determine if, in an equal access health care system, racial differences in the receipt of AHT exist. We evaluated 494 study-eligible, Black (n = 255) and White women (n = 269) who were under 65 years old and diagnosed with stages I-III, HR? breast cancers between 2004 and 2007. Bivariate and multivariate analyses were conducted to assess receipt of C1 AHT prescriptions at any point in time following (ever-use) or within 12 months of (early-use) breast cancer diagnosis. Seventy-two percent of the participants were ever-users (70 % Black, 74 % White) and 68 % were early-users No racial variations in use of AHT among women with HR? breast cancers insured by Medicaid in South Carolina were identified, but overall rates of AHT use by these women is low. Strategies to improve overall use of AHT should include targeting breast cancer patients who do not receive adjuvant chemotherapy and/or radiation.
Introduction
While breast cancer survival rates have improved over time, the disparities in mortality rates between Black and White women with breast cancer have widened [1] . Black women are 41 % more likely to die from breast cancer than White women, even though Black women are less likely to be diagnosed with the disease [2] . Compared to White women in South Carolina (SC), Black women's death rate from breast cancer is more than 60 % higher [3] . Their risk of breast cancer death further increases if they are from socioeconomically disadvantaged (e.g., Medicaid-eligible) backgrounds [4] .
A prior study of low-income women in a governmentfunded screening program in SC reported that Black and White women with newly diagnosed breast cancers presented at similar stages, but Black women were significantly more likely to be diagnosed with tumors of poor-prognosis phenotype [5] . While these findings suggest that biologic differences might account for the racial disparity in breast cancer mortality in SC, another key factor-differential use of treatments, such as adjuvant hormonal therapy (AHT) [6] -could be contributing to this racial divide.
Worldwide, the use of AHT has led to a significant reduction in breast cancer mortality for women with earlystage, hormone receptor-positive breast cancers (HR?) [7] . Following the receipt of breast cancer surgery (lumpectomy or mastectomy), oncologists often recommend women with HR?, early-stage breast cancers to receive a combination of adjuvant therapies, including chemotherapy, radiation, and AHT. For AHT, clinical guidelines recommend tamoxifen, and/or aromatase inhibitor (AI) be taken daily for 5-10 years depending on menopausal status [8, 9] . As a measure of quality breast cancer care, guidelines further suggest that clinically eligible women initiate AHT within 12 months of diagnosis [10] . This analysis investigates racial differences in the use of AHT among low-income women diagnosed with HR? breast cancer who have equal access to medical and pharmaceutical care through SC Medicaid.
Materials and methods

Data sources
This study was approved by the Institutional Review Board of the University of South Carolina and SC Department of Health and Environmental Control. Data from the population-based SC Central Cancer Registry (SCCCR) were used to identify all primary cases of breast cancers from 2004 to 2007 and linked to Medicaid enrollment/claims. The SCCCR has received either gold or silver certification for the completeness, accuracy, and timeliness of its data since 1997. The SCCCR provided socio-demographic (e.g., race, marital status, age, county of residence) and cancer-specific information (e.g., stage, tumor grade, hormone receptor status) at the time of primary breast cancer diagnosis. Medicaid offered monthly records of all linked cancer beneficiaries' ''fee-for-service'' medical, hospital, and pharmacy claims from 2003 to 2008. Medicaid files contained beneficiaries' diagnosis and procedure field codes by the International Classification of Disease, ninth Revision (ICD-9), and Current Procedural Terminology (CPT)/Healthcare Common Procedure Coding System (HCPCS) schema. Urban influence codes classifying patient county residence based on county population size, level of urbanization, and access to larger communities were obtained from a publicly available data file from the U.S. Department of Agriculture [11] . Figure 1 summarizes our study inclusion criteria. Women aged 65 or older at diagnosis were excluded (n = 220) because the administration of pharmacy benefits for Medicaid-Medicare ''dual-eligibles'' would have transferred from SC Medicaid to Medicare Part D in 2006 which overlapped our study period. Races other than Black or White were also excluded (n = 10). The final analytic sample was n = 494.
Study eligibility
Study outcomes
We examined whether patients received AHT at any point in time following diagnosis (ever-use), as defined by those who had at one or more Medicaid pharmacy claims for any AHT agent during our study period. We also examined whether patients received AHT within 12 months of diagnosis (early-use) defined as having an initial Medicaid pharmacy claim for any type of AHT agent within 12 months of their breast cancer diagnosis. AHT was defined as an AI or tamoxifen, as ascertained by generic drug name and therapeutic drug code in the Medicaid pharmacy files.
Independent variables
Our key variable of interest was race (Black vs. White). Other socio-demographics were marital status (married vs. not married), age (\45, 45-54, 55-64 years old), rurality of county of residence (small/large metropolitan, micropolitan, non-core/non-metropolitan), and Medicaid eligibility status (disabled vs. not disabled). Cancer-specific clinical characteristics included year of diagnosis, stage, tumor grade, and HR status. We categorized stages 1 and 2 as local, and stages 3, 4 or 5 as regional stage using the Surveillance Epidemiology and End Results summary stages [12] . We categorized tumor stage as I, II, and III-IV or unknown/unavailable. Hormone receptor-positive status consists of three potential classifications for estrogen (ER? or ER-) and progesterone receptors (PR? or PR-): ER?/ PR?, ER?/PR-, ER-/PR?. Given the distribution of hormone status in our population, we dichotomized HR status: ER?/PR? (77 %) versus other combinations [ER?/ PR-(19 %), ER-/PR? (4 %)]. We used ICD-9 and CPT/ HCPCS codes within the Medicaid claims to identify additional breast cancer treatment-specific factors: receipt (yes vs. no) of breast cancer surgery (lumpectomy or mastectomy), chemotherapy, and radiation. We also used ICD-9 grouping methods to construct the Deyo-adapted Charlson co-morbidity scores [13] (Procedural codes used in this study are available from the first author by request).
Data analysis
We conducted descriptive statistics and bivariate analyses to estimate the association between ever-use and early-use to the independent variables. We then constructed two separate multivariate regression models to examine each of the outcomes in relation to race and other clinical and socio-demographic variables.
Results
A total of 225 (46 %) Black and 269 (54 %) White women were eligible for the study (Table 1) . Most women were diagnosed with ER?/PR? tumors (77 %) and generally received some form of surgery (60 %), chemotherapy (52 %), or radiation (54 %). Descriptive statistics by race indicated that Blacks versus Whites, were more likely to be diagnosed with grade III-IV or unknown tumors (58 % vs. 32 %, p \ 0.001) and receive chemotherapy (62 % vs. 51 %, p = 0.016). Seventy-two percent of women were ever-users (70 % Black, 74 % White, p = 0.346) and 68 % were early-users (65 % Black, 71 % White, p = 0.146) of AHT. 
Ever-users
Early-users
With respect to early-use (Table 2 ), unadjusted models indicated that there was no statistically significant association between race and early-use of AHT (p = 0.147). However, the odds of early-use of AHT were significantly higher for women who received surgery (OR = 2.50, 95 % CI 1.70-3.68) chemotherapy (OR = 2.19, 95 % CI 1.49-3. 
Discussion
We found that among low-income women in South Carolina who were diagnosed with HR?, early-stage breast cancers and insured by Medicaid, rates of ever-use and use of AHT within guideline recommendations (early-use) were similar for Black and White women. This finding is consistent with previous studies of Medicaid-enrolled breast cancer survivors in New York [14] and North Carolina [15] , which also did not identify significant differences in AHT use by race after controlling for other factors. Comparatively, within more heterogeneous samples with respect to race/ethnicity, health insurance, and socioeconomic backgrounds, studies report lower use of AHT among African Americans [16, 17] , women living in high-poverty areas [18] , and those insured by Medicaid or uninsured patients [17] . Hershman et al. (2015) recently found that the combination of Black race (vs. White) and low net worth significantly reduced the odds of adhering to AHT [19] . Results from our study and the aforementioned work of others suggest that socioeconomic factors are a driving force to the differences in the use of AHT between Blacks and Whites. While we did not find racial differences in the use of AHT, we did observe that nearly one-third of women in our study had no pharmacy claims for AHT indicating that they either did not fill their prescription or were not prescribed AHT. This is particularly troubling given that AHT improves survival and is covered by SC Medicaid. Others have documented low use of AHT in Medicaid populations ranging from 50 to 58 % within the first year [14, 20] , compared to 85 % in a privately insured population [21] and 72-92 % in clinical trials [22] . It is suggested that low use of AHT among racial/ethnic and low socioeconomic populations (e.g., Medicaid enrollees) are due, in part, to variations in barriers experienced by these subgroups, such as in patient-centered communication and access to community resources [23] .
Of note, we did find that women who received breast surgery, chemotherapy, or radiation treatments were twice as likely to be ever-and early-users of AHT compared to their counterparts. Oncologists base recommendations for chemotherapy and/or radiation on the specific characteristics of the patient's breast cancer (e.g., stage, tumor size, lymph node status, etc.). Patients who receive these additional treatments will have more interactions with cancer care providers, thus, providing more opportunities for them to receive their AHT prescription, obtain information about AHT, and discuss potential issues or concerns about their AHT with their oncology providers. Patients who receive adequate information about AHT and understand why they need it, are more likely to take their AHT as prescribed [24] .
Our study has limitations. First, SCCCR-Medicaid data does not include information on patient or provider attitudes and beliefs that play an important role in AHT use [25, 26] . Second, because Medicaid claims are collected for administrative versus research purposes, administrative changes in the SC Medicaid program may have led to some misclassification of our outcome. For instance, the finding that early-use of AHT decreased after 2006 may be due, in part, to changes in SC Medicaid following implementation of the state's Medicaid Breast and Cervical Treatment Program in 2005. Third, these changes could also account for the low rates of surgery in our study. Wheeler et al. (2014) found a similar concern, in that 22 % of the Medicaid-enrolled breast cancer patients in North Carolina had no claims for surgery [20] . An alternative explanation for our low rates of surgery could be that some patients receive surgery prior to Medicaid enrollment. Given that patients enroll in Medicaid pre/post cancer diagnosis for various reasons (e.g., loss of private insurance), treatment information from Medicaid files may be incomplete [27, 28] . Fourth, for women who had no Medicaid pharmacy claims for AHT, we are unable to determine if they were never prescribed or received AHT from support services, such as pharmaceutical assistance programs. For example, AIs accounted for nearly 40 % of all agents received by financially indigent cancer patients enrolled in pharmaceutical assistance programs at a large cancer care hospital [29] . Finally, this study included only Medicaid enrollees from SC, so generalizability beyond this setting and time period cannot be assumed.
While we reassuringly did not find evidence of racial variations in AHT in our Medicaid population, it was not because rates of AHT use for Black and White women were similarly high, but rather that these rates were similarly low. Among Medicaid enrollees diagnosed with HR? breast cancers, particular attention should be placed on exploring reasons why they may not receive or fill prescriptions for AHT, as well as, improving overall use of AHT. Targeted strategies to improve use of AHT are also particularly needed for those women who do not receive other adjuvant treatments, such as chemotherapy or radiation.
